TAmiRNA and SimplicityBio join forces to improve microRNA biomarker development

TAmiRNA and SimplicityBio, a Swiss bioinformatics company specialized in in silico biomarker discovery, signed a partnership agreement. The aim of this partnership is to accelerate TAmiRNA´s biomarker development programs and to offer compelling biomarker development services to clients from academia and biotech industry.

The first aim of the partnership is the acceleration of TAmiRNA´s ongoing microRNA biomarker projects. The second is to offer one-stop biomarker development services to clients in need of diagnostic solutions for early diagnosis, prognosis, or patient stratification.

This partnership consolidates TAmiRNAs development pipeline and strengthens the competing power of SimplicityBio´s and TAmiRNA´s biomarker discovery and development services.

Moreover it will improve microRNA biomarker development and advance existing microRNA biomarker signatures to make them more sensitive, specific and robust.

More information:

SimplicityBio is Swiss based company, founded in 2015 and active in the discovery of novel medical biomarkers by means of its patented bioinformatics machine-learning technology. SimplicityBio aims to be the reference and improve drastically patient lives with new diagnostics enabling personalised medicine.


The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.